These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36454436)

  • 1. Clinical Characteristics and Management of Children and Adults with Neurofibromatosis Type 1 and Plexiform Neurofibromas in Denmark: A Nationwide Study.
    Ejerskov C; Farholt S; Nielsen FSK; Berg I; Thomasen SB; Udupi A; Ågesen T; de Fine Licht S; Handrup MM
    Oncol Ther; 2023 Mar; 11(1):97-110. PubMed ID: 36454436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. French cohort of children and adolescents with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas: CASSIOPEA study.
    Wolkenstein P; Chaix Y; Entz Werle N; Amini-Adle M; Barbarot S; Boileau C; Miled A; Rashid T; Aerts I
    Eur J Med Genet; 2023 May; 66(5):104734. PubMed ID: 36868501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
    Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
    BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between benign and malignant peripheral nerve sheath tumors in NF1.
    Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM
    Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical management of peripheral nerve sheath tumours in children, with special consideration of neurofibromatoses.
    Zipfel J; Al-Hariri M; Gugel I; Haas-Lude K; Grimm A; Warmann S; Krimmel M; Mautner VF; Tatagiba M; Schuhmann MU
    Childs Nerv Syst; 2020 Oct; 36(10):2433-2442. PubMed ID: 32506255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.
    Ferner RE; Lucas JD; O'Doherty MJ; Hughes RA; Smith MA; Cronin BF; Bingham J
    J Neurol Neurosurg Psychiatry; 2000 Mar; 68(3):353-7. PubMed ID: 10675220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18-fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with Neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST).
    Meany H; Dombi E; Reynolds J; Whatley M; Kurwa A; Tsokos M; Salzer W; Gillespie A; Baldwin A; Derdak J; Widemann B
    Pediatr Blood Cancer; 2013 Jan; 60(1):59-64. PubMed ID: 22645095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient characteristics, treatment patterns, healthcare resource utilization, and costs among patients diagnosed with neurofibromatosis type 1 with and without plexiform neurofibromas in Japan.
    Yoshida Y; Tozawa K; Koto R; Iwao C; Kim Y; Ban L; Barut V
    Curr Med Res Opin; 2024 Apr; 40(4):723-731. PubMed ID: 38404173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas.
    Tucker T; Friedman JM; Friedrich RE; Wenzel R; Fünsterer C; Mautner VF
    J Med Genet; 2009 Feb; 46(2):81-5. PubMed ID: 18930997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.
    Weiss B; Widemann BC; Wolters P; Dombi E; Vinks A; Cantor A; Perentesis J; Schorry E; Ullrich N; Gutmann DH; Tonsgard J; Viskochil D; Korf B; Packer RJ; Fisher MJ
    Neuro Oncol; 2015 Apr; 17(4):596-603. PubMed ID: 25314964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey.
    Yoo HK; Porteous A; Ng A; Haria K; Griffiths A; Lloyd A; Yang X; Kazeem G; Barut V
    BMC Neurol; 2023 Nov; 23(1):419. PubMed ID: 37996843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.
    Tsai LL; Drubach L; Fahey F; Irons M; Voss S; Ullrich NJ
    J Neurooncol; 2012 Jul; 108(3):469-75. PubMed ID: 22407214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
    Kim A; Gillespie A; Dombi E; Goodwin A; Goodspeed W; Fox E; Balis FM; Widemann BC
    Neurology; 2009 Oct; 73(16):1273-9. PubMed ID: 19841379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
    Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
    Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene.
    Friedrich RE; Kluwe L; Fünsterer C; Mautner VF
    Anticancer Res; 2005; 25(3A):1699-702. PubMed ID: 16033085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
    Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR
    Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics, treatment patterns, healthcare resource use, and costs among pediatric patients diagnosed with neurofibromatosis type 1 and plexiform neurofibromas: a retrospective database analysis of a medicaid population.
    Yang X; Desai K; Agrawal N; Mirchandani K; Chatterjee S; Sarpong E; Sen S
    Curr Med Res Opin; 2021 Sep; 37(9):1555-1561. PubMed ID: 34218725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.
    Pemov A; Li H; Patidar R; Hansen NF; Sindiri S; Hartley SW; Wei JS; Elkahloun A; Chandrasekharappa SC; ; Boland JF; Bass S; ; Mullikin JC; Khan J; Widemann BC; Wallace MR; Stewart DR
    Oncogene; 2017 Jun; 36(22):3168-3177. PubMed ID: 28068329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience.
    Espírito Santo V; Passos J; Nzwalo H; Carvalho I; Santos F; Martins C; Salgado L; Silva CE; Vinhais S; Vilares M; Salgado D; Nunes S
    J Neurooncol; 2020 Apr; 147(2):459-463. PubMed ID: 32108293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
    Friedrich RE; Beer C; Glatzel M; Hagel C
    Anticancer Res; 2015 Jan; 35(1):137-44. PubMed ID: 25550544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.